Clearpoint Neuro (CLPT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual Meeting of Stockholders scheduled for May 20, 2026, to be held virtually at 10:00 AM Pacific Time.
Stockholders can vote electronically or request paper copies of proxy materials.
Proxy materials include the 2026 Proxy Statement, 2025 Annual Report, and Proxy Card.
Voting matters and shareholder proposals
Election of seven directors to serve until the 2027 Annual Meeting.
Ratification of Cherry Bekaert LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory (non-binding) vote to approve executive compensation.
Approval of the Seventh Amended and Restated 2013 Incentive Compensation Plan.
Consideration of other matters that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Seven director nominees are presented for election for a one-year term ending at the 2027 Annual Meeting.
Latest events from Clearpoint Neuro
- Annual meeting to vote on directors, auditor, executive pay, and expanded equity plan.CLPT
Proxy filing10 Apr 2026 - Four-pillar strategy drives neuro innovation, aiming for $200m+ revenue and global leadership.CLPT
Corporate presentation17 Mar 2026 - Record 2025 revenue and IRRAS acquisition drive double-digit growth outlook for 2026.CLPT
Q4 202517 Mar 2026 - Q2 revenue up 32% to $7.9M; guidance raised, margins expand, and global growth accelerates.CLPT
Q2 20242 Feb 2026 - Q3 revenue up 41% to $8.1M, gross margin 60%, debt repaid, 2024 guidance $30–33M.CLPT
Q3 202415 Jan 2026 - Registering 1,312,570 shares for resale post-IRRAS acquisition; no proceeds to the company.CLPT
Registration Filing14 Jan 2026 - 2024 revenue up 31% to $31.4M; 2025 guidance $36–41M, fueled by FDA wins and global growth.CLPT
Q4 202423 Dec 2025 - Shareholders will vote on director elections, compensation, and expanded equity plans.CLPT
Proxy Filing1 Dec 2025 - Q1 revenue up 11% to $8.5M, with robust neurosurgery growth and new funding secured.CLPT
Q1 202527 Nov 2025